Gardasil HPV vaccine lawsuit MDL 3036: the POTS and autoimmune claims, the summary judgment on preemption now before the Fourth Circuit, the mandatory VICP prerequisite, and why the design-defect path is closed
The Gardasil litigation is one of the more legally complicated mass torts currently pending, and anyone evaluating a potential claim needs to understand why before anything else. The cases are consolidated as In re: Gardasil Products Liability Litigation, MDL 3036, in the U.S. District Court for the Western District of North Carolina. The plaintiffs allege that Merck's HPV vaccine, Gardasil and its successor Gardasil 9, caused serious injuries including postural orthostatic tachycardia syndrome (POTS), autoimmune disorders, and primary ovarian insufficiency (POI).
But unlike most pharmaceutical mass torts, the Gardasil litigation faces two structural legal barriers that are unique to vaccines, plus a recent summary judgment ruling that has put the entire litigation in jeopardy. Understanding these barriers is essential, because they determine whether a Gardasil claim can proceed at all.
This is not a "Gardasil payout" story. The litigation is real and active, but it is at a precarious moment, and the honest assessment is that its future depends substantially on a pending appeal to the Fourth Circuit.
The vaccine and the alleged injuries
Gardasil, manufactured by Merck and Co., was approved by the FDA in 2006 to prevent infection by human papillomavirus (HPV), a sexually transmitted virus linked to cervical, anal, and other cancers, as well as genital warts. Gardasil 9, the successor vaccine, protects against additional HPV strains. Hundreds of millions of doses have been administered worldwide.
The plaintiffs allege that the vaccine caused serious, long-term injuries:
POTS (postural orthostatic tachycardia syndrome), a disorder of the autonomic nervous system causing rapid heart rate, dizziness, fatigue, and fainting on standing.
Autoimmune disorders, in which the immune system attacks the body's own tissues.
Primary ovarian insufficiency (POI), also called premature ovarian failure, affecting reproductive function.
Chronic fatigue, neurological injuries, and other conditions.
The Vaccine Adverse Event Reporting System (VAERS) has received thousands of reports of serious adverse events following Gardasil vaccination. The plaintiffs allege that Merck knew of these risks, failed to adequately warn patients and physicians, and in some allegations manipulated clinical trial data to obscure safety signals.
Barrier one: the VICP must come first
The first thing any potential Gardasil claimant must understand is that you generally cannot sue Merck directly without first going through the National Vaccine Injury Compensation Program (VICP).
The VICP is a federal no-fault compensation system created by the National Childhood Vaccine Injury Act of 1986 (NCVIA). For vaccines covered by the program (which includes HPV vaccines), the NCVIA requires that an injured person first file a petition with the VICP (sometimes called the "Vaccine Court," administered through the U.S. Court of Federal Claims) before pursuing a civil lawsuit against the manufacturer. You can learn about the program through the Health Resources and Services Administration's VICP overview.
The VICP has a strict filing deadline: generally, a petition must be filed within 3 years of the first symptom of the injury (or within 2 years of a death, and 4 years after the first symptom for a death claim). This deadline is firm and unforgiving. For many potential Gardasil claimants, the VICP deadline may already have passed, because the symptoms appeared years before the person connected them to the vaccine.
Only after the VICP process concludes (and if the claimant rejects the VICP outcome) can the person proceed to a civil lawsuit against Merck. The VICP prerequisite has substantially limited how many cases reach the civil MDL.
Barrier two: design-defect claims are preempted
The second structural barrier comes from the Supreme Court. In Bruesewitz v. Wyeth, 562 U.S. 223 (2011), the Court held that the NCVIA preempts design-defect claims against vaccine manufacturers. The reasoning: Congress, in the NCVIA, made a policy choice to protect vaccine manufacturers from design-defect liability (to ensure a stable vaccine supply), channeling injury claims through the VICP instead.
The practical effect for the Gardasil litigation: plaintiffs cannot argue that the vaccine was defectively designed. That theory is off the table. The Gardasil cases must proceed, if at all, on failure-to-warn and fraud theories, alleging that Merck failed to warn about risks it knew or should have known about, or misrepresented the vaccine's safety.
This is why the failure-to-warn claims are the heart of the litigation. With design defect preempted by Bruesewitz, failure to warn is the primary surviving theory. And that theory is precisely what the recent summary judgment ruling addressed.
The summary judgment blow
In a development that reshaped the litigation, the MDL court granted Merck summary judgment on the failure-to-warn claims, on grounds of implied preemption.
The court's reasoning tracked the same logic that has appeared in other pharmaceutical preemption fights. Merck argued that it could not have unilaterally added warnings about POTS and POI to the Gardasil label, because the FDA had never required such warnings and had consistently rejected the contention that Gardasil causes those conditions. Under federal law, a manufacturer cannot add a warning the FDA would not approve; if Merck could not have added the POTS and POI warnings, then the state-law failure-to-warn claims (which would require those warnings) are preempted.
The court agreed, finding that Merck could not have independently added the warnings without FDA approval, and that since the FDA had never required them, the failure-to-warn claims were preempted. For a litigation built primarily on failure to warn (with design defect already foreclosed by Bruesewitz), this was a substantial blow.
The Fourth Circuit appeal
The plaintiffs have appealed the summary judgment ruling to the U.S. Court of Appeals for the Fourth Circuit. The appeal challenges both the preemption ruling and related rulings that excluded key expert testimony on causation.
The appeal is the pivotal event in the litigation. If the Fourth Circuit reverses, the failure-to-warn claims are revived and the litigation can proceed toward bellwether trials. If the Fourth Circuit affirms, the failure-to-warn claims remain foreclosed, and the litigation is effectively over for the affected plaintiffs.
As of 2026, no bellwether trials are scheduled, and the litigation is essentially paused pending the appeal. The case count has grown slowly (to roughly 200 cases in the federal MDL, with the pace of new filings slowing as the appeal's outcome remains uncertain). This is a litigation in suspended animation, waiting on an appellate decision that will determine whether it lives or dies.
The state court track
Separately from the federal MDL, some Gardasil cases have proceeded in state court, particularly in California. State court cases are not bound by the federal MDL's preemption ruling (though they face the same Bruesewitz design-defect bar and the same federal preemption arguments, which state courts analyze independently).
The state court track has, at times, moved faster than the federal MDL. For potential claimants, the choice of forum (and whether a state court claim is viable) is a strategic question that depends on the specific facts and the applicable state law.
How Gardasil compares to other preemption-driven mass torts
The Gardasil litigation shares its central legal dynamic with several other Halstonberg-covered mass torts where federal preemption is the decisive issue:
Depo-Provera meningioma (MDL 3140) involves the same implied-preemption defense, with Pfizer arguing that the FDA's labeling decisions preempt the failure-to-warn claims. The Gardasil preemption ruling illustrates the risk that the Depo-Provera litigation could face if its preemption defense succeeds.
Ozempic and GLP-1 gastroparesis (MDL 3094) similarly turns on the adequacy of warnings and the FDA's labeling authority, though the GLP-1 drugs are not subject to the vaccine-specific NCVIA framework.
Hair relaxer uterine cancer (MDL 3060) is a failure-to-warn case without the vaccine-specific barriers, which illustrates how much harder the Gardasil litigation is by comparison: the vaccine cases must clear the VICP prerequisite, the Bruesewitz design-defect bar, and the implied-preemption defense, while a cosmetic-product case faces none of those.
The comparison underscores the central point: vaccines occupy a unique and heavily protected legal position. The NCVIA, the VICP, and Bruesewitz combine to make vaccine injury litigation substantially more difficult than ordinary pharmaceutical or product litigation.
Practical guidance
For someone who received Gardasil and believes they suffered a serious injury:
Understand the VICP prerequisite and its deadline first. You generally must go through the VICP before suing Merck, and the VICP deadline (typically 3 years from the first symptom) is firm. If you have not yet filed a VICP petition and your symptoms appeared within the deadline window, the VICP filing is the urgent first step. Consult a vaccine injury attorney immediately to evaluate your timeline.
Understand that the civil litigation is currently imperiled. The failure-to-warn claims have been dismissed on preemption grounds, and the litigation's future depends on the Fourth Circuit appeal. A civil claim against Merck faces substantial legal headwinds unless and until the appeal succeeds.
Understand that design-defect claims are not available. Bruesewitz forecloses the argument that the vaccine was defectively designed. Any civil claim must rest on failure to warn or fraud.
Gather your documentation regardless. Medical records confirming the injury (the POTS diagnosis, the autoimmune workup, the POI diagnosis), the vaccination records establishing the Gardasil administration and timing, and the symptom timeline (which is critical for both the VICP deadline and causation) are the foundation of any claim, whether in the VICP or in civil court.
Be especially cautious about advertising. The Gardasil litigation has attracted substantial marketing that often overstates the prospects, glossing over the VICP prerequisite and the preemption ruling. The accurate picture is that this is a difficult, appeal-dependent litigation. Counsel who handle vaccine injury cases (and who will be candid about the VICP process and the appeal) are the appropriate contact.
The Gardasil litigation is a case study in how the legal architecture around vaccines shapes injury claims. The NCVIA's no-fault VICP system, the Bruesewitz design-defect bar, and the implied-preemption defense together make these claims uniquely challenging. For affected individuals, the realistic path runs through the VICP first; the civil litigation against Merck remains possible but is currently waiting on an appellate decision that will determine its survival.